<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00950456</url>
  </required_header>
  <id_info>
    <org_study_id>820901</org_study_id>
    <nct_id>NCT00950456</nct_id>
  </id_info>
  <brief_title>Observational Study to Assess Safety of H1N1 Pandemic Influenza Vaccine</brief_title>
  <official_title>A Prospective Non-Interventional Observational Study to Assess the Safety of Two Vaccinations of a Vero Cell-Derived, Whole Virus H1N1 Pandemic Influenza Vaccine in Subjects Exposed to the Vaccine Through Policies by Governments or Health Authorities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ology Bioservices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ology Bioservices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study, which will be initiated as soon as the licensed H1N1
      Pandemic Influenza Vaccine is used in a mass vaccination campaign, is to estimate the
      incidence of any medically-attended adverse events in all vaccinated subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3216</enrollment>
  <condition>Influenza</condition>
  <condition>Pandemic Influenza</condition>
  <arm_group>
    <arm_group_label>H1N1 Pandemic Influenza Vaccine</arm_group_label>
    <description>Subjects will be enrolled and vaccinated according to national policy and standard practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)</intervention_name>
    <description>It is anticipated that subjects will receive two intramuscular injections approximately 3 weeks apart. The vaccine will be provided in two doses, one for adults, the other for children.</description>
    <arm_group_label>H1N1 Pandemic Influenza Vaccine</arm_group_label>
    <other_name>CELVAPAN</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The enrollment of subjects in this study will follow national vaccination policy decisions
        in the UK.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male and female subjects, per indication on license or per official vaccine
        recommendations, will be eligible for participation in this study if:

          -  They will be administered CELVAPAN (= BaxterÂ´s H1N1 pandemic influenza vaccine)

          -  They are 2 months of age or older at the time of first vaccine administration

          -  Their medical history is available

          -  The investigator believes they will comply with the foreseen vaccination schedule and
             will reliably observe signs or symptoms of adverse events during the observational
             period

          -  They and/or their parent(s)/legal guardian(s) provide written informed consent, and
             assent where appropriate, prior to study entry according to national law

        Exclusion Criteria:

        Male and female subjects will be excluded from participation in this study if:

          -  They have already been administered another H1N1 pandemic vaccine

          -  They have any contraindication to vaccination (as per the Summary of Product
             Characteristics and/or relevant national immunization guidelines)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baxter BioScience Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Healthcare Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Practice</name>
      <address>
        <city>Bludenz</city>
        <zip>6700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Practice</name>
      <address>
        <city>Fulpmes</city>
        <zip>6166</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Practice</name>
      <address>
        <city>Hall in Tirol</city>
        <zip>6060</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Practice</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Practice for Travel Medicine</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Council (Magistrat) Klagenfurt (Health &amp; Food Department)</name>
      <address>
        <city>Klagenfurt</city>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Practice</name>
      <address>
        <city>Kufstein</city>
        <zip>6330</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Practice</name>
      <address>
        <city>Mariapfarr</city>
        <zip>5571</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Practice</name>
      <address>
        <city>Oberperfuss</city>
        <zip>6173</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Practice</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Practice</name>
      <address>
        <city>Telfs</city>
        <zip>6410</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Specific Prophylaxis and Tropical Medicine</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanusch Hospital</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wiener Gebietskrankenkasse (Health insurance center Vienna)</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Practice</name>
      <address>
        <city>Voitsberg</city>
        <zip>8570</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Practice</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2009</study_first_submitted>
  <study_first_submitted_qc>July 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2009</study_first_posted>
  <last_update_submitted>October 7, 2015</last_update_submitted>
  <last_update_submitted_qc>October 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2015</last_update_posted>
  <responsible_party>
    <name_title>David Perry, MD; SponsorÂ´s signatory</name_title>
    <organization>Baxter Innovations GmbH</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

